Get Access to Breakthrough New Cancer Therapies with Clinical Trials at Astera Cancer Care
At Astera Cancer Care, we’re committed to providing you or your loved one real hope against cancer. This means we’re dedicated to being on the leading edge of cancer care and to the discovery of new therapies, breakthrough treatment approaches, and new options for extending life.
We’re investigating tomorrow’s treatments today.
If you or someone you love is being treated for cancer without success, clinical trials can offer new hope. Clinical trials are how all treatments are investigated for their safety and effectiveness. As such, every treatment in use today was first studied through clinical trials, and the first people helped by any treatment were those who participated in its clinical trial.
Access to major studies—and new reason for hope—close to home.
At Astera Cancer Care, you have access to a wide variety of advanced clinical trials and breakthrough alternative therapies you might expect only from large, crowded metropolitan cancer treatment centers, but right here close to home. With frequent visits and follow-ups inherent in clinical research studies, our proximity reduces a significant amount of burden on patients and family members.
As a study participant at Astera Cancer Care, you would not only have close-to-home access to next-generation therapies for yourself but would also be helping to advance research in key areas, like:
- Non-Hodgkin lymphoma
- Breast cancer
- Ovarian cancer
- Prostate cancer
- Locally advanced or metastatic solid tumors
- And more
What’s more, we participate in trials for which we are the only community-based participant or just one of a small handful in the United States, giving you or your loved one access to new therapies that could otherwise be unavailable to you. At the same time, we are dedicated to your safety and to restoring your hope for treatment success.
Clinical Trials at Astera Cancer Care Currently Seeking Qualified Patients
Below are the studies in which Astera Cancer Care participates that are currently enrolling new patients. Contact our clinical research department at 732-783-5183 about the study or studies that interest you to begin the process of determining your eligibility.
|Title||A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting|
|Title||A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors|
|Title||A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma|
|Title||A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) (SKYSCRAPER-03)|
|Title||A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination With Azacitidine in Patients Newly Diagnosed With Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS)|
|Title||A Phase 3, Randomized, Double-Blind, Active and Placebo-Controlled Study on the Use of CUSA-081 for Dysfunctional Central Venous Access Devices (CVADs)|
|Title||CLINICAL PROTOCOL for the INVESTIGATION Of the ProSpace™ Balloon System Pivotal Study BP-007|
|Title||BESPOKE Study of ctDNA Guided Therapy in Colorectal Cancer|
|Title||An Exploratory Biomarker Study of Checkpoint Inhibitors (PD-1, PD-L1 and CTLA-4) used as Monotherapy or In Combination In Patients with Cancer|
|Title||PREVAIL: A Prospective, Non-Interventional Study to Assess the Prevalence of PD-L1 Expression in the First-Line Setting of Locally Advanced/Unresectable or Metastatic Urothelial Carcinoma|
|Title||A Multicenter, Low-Interventional Study to Evaluate the Feasibility of a Prospective Clinicogenomic Program|
Learn more about Astera Cancer Care’s ongoing clinical trials to see if you qualify to participate in a study for access to breakthrough cancer therapies. Contact our clinical trials department directly at 732-783-5183 ext. 0231 or 0253. Or request an appointment using our easy and convenient online form.